Iveson T.J., AHern J., Smith I.E.
Response to third line endocrine treatment for
advanced breast cancer // Eur. J. Cancer. 1993. V. 29A. P. 572 574.
Jaffe H.L.
Tumors and tumorous conditions of bones and joints // Philadelphia: Lea
and Febiger. 1958.
Jain S., Fisher C., Smith P., Millis R.R., Rubens R.D.
Patterns of metastatic breast
cancer in relation to histological type // Eur. J. Cancer. 1993. V. 29A(15). P. 2155
2157.
Janjan N.A.
Radiation for bone metastases: conventional techniques and the role of
systemic radiopharmaceuticals // Cancer. 1997. V. 80(Suppl. 8). P. 1628 1645.
Jiang C.Y., Zhu B.L., Zhang Y.J.
The value of Sm 153 EDTMP for treatment of
metastatic bone pain and improving quality of life // Chung Hua Chung Liu Tsa Chih.
1994. V. 16(2). P. 118 121.
Jiang Z., Song S., Li J.
Clinical trial of high dose medroxyprogesterone acetate in
advanced breast cancer // Chung Hua Chung Liu Tsa Chih. 1995. V. 17(1).
P. 71 73.
Johnson P.A., Bonomi P.D., Anderson K.M., Wolter J.M., Rossoff A.H., Economou
S.G.
Megestrol acetate (MA) in advanced breast cancer: reasponse rate related to oestro
gen receptor (ER) and progesterone receptor (PR) levels // Proceedings of the American
Association of Clinic. Oncology. 1982. I. P. 89.
Johnson J.R., Priesman T.J., Fotherby K., Kelly K.A., Priesman S.G.
An evalution of
high dose medroxyprogesterone acetate (MPA) therapy in women with advanced breast
cancer // Brit. J. Cancer. 1984. V. 50. P. 363 366.
Johnston M.J., Lipsett J.A., Donovan A.J.
Osseous metastasis in mammary cancer //
Arch. Surg. 1970. V. 101. P. 578 581.
Jones S.E., Duric B.G.M., Salmon S.E.
Combination chemotherapy with adriamycin
and cyclophosphamide for advanced breast cancer // Cancer. 1975. P, 90 97.
Jones A.L., Williams M.P., Powles T.J., Oliff J.F.C., Hardy J., Cherryman G.R.,
Husband J.E.
Magnetic resonance imaging in the detection of skeletal metastases in
patients with breast cancer // Br. J. Cancer. 1990. V. 62. P. 296 298.
Jones S., Vogel C., Fehrenbacher L.,
่ ๑๎เโ๒. A phase II study of antitumor efficacy
and safety of exemestane as third line hormonal treatment of postmenopausal patients
with metastatic breast cancer (MBC) refractory to tamoxifen and megace // Eur. Soc.
Oncol. 1998. V. 9(suppl. 4). P. 13.
Jones S., Belt R., Cooper B.,
่ ๑๎เโ๒. A phase II study of antitumor efficacy and safe
ty of exemestane (EXE) as second line hormonal treatment of postmenopausal patients
with metastatic breast cancer (MBC) refractory to tamoxifen // Breast Cancer Res. Treat.
1998. V. 50. P. 304.
Jonston A.D.
Pathology of metastatic tumor in bone // Clin. Orthop. 1970.
V. 73. P. 8 32.
Kadama H.
Preoperative bone scintigraphy in breast cancer problem of preoperative
stading // J. Jap. Soc. Cancer Ther. 1976. V. 297. P. 678 698.
Kamby C., Egsmose C., Soletormos G., Dombernowsky P.
The diagnostic and prog
nostic value of serum bone Gla protein (osteocalcin) in patients with recurrent breast can
cer // Scand. J. Clin. Lab. Invest. V. 53(5). P. 439 546.
Kanis J.A., Cundy T., Heynen G., Russell R.G.G.
The pathophysiology of hypercal
caemia // Metab. Bone Dis. Rel. Res. 1980. V. 2. P. 143 159.
232
ส๎๑๒ํ๛ๅ ์ๅ๒เ๑๒เ็๛ ๐เ๊เ ์๎๋๎๗ํ๎้ ๆๅ๋ๅ็๛
